Ocellaris Pharma, Inc.   Report issue

For profit Phase 2
Founded: Montreal Canada (2019)

Organization Overview

First Clinical Trial
2020
NCT04260802
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ocellaris Pharma, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

oc-001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Second Primary (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1